Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-blind placebo-controlled study of adjunctive OV329 in adults with drug-resistant focal epilepsy
MOH_2026-04-20_015776Phase 2Not yet recruiting
- Sponsor
- Ovid Therapeutics
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Focal Onset Epilepsy comparing OV329 plus background antiseizure medications with Placebo plus background antiseizure medications (2 arms). Primary endpoint: Not reported. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
OV329
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on MOH_2026-04-20_015776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-04-20_015776.